Research Triangle Park, North Carolina
January 6, 2006
Athenix Corp., a
leading biotechnology company developing novel products,
technologies, and processes for agricultural and chemical
applications, announced today it has raised $13 million in
growth capital through a Series C venture capital investment.
The Series C round was led by new investor Finistere Partners of
San Diego, California, with continued strong participation from
the entire existing investor group: Intersouth Partners of
Durham, North Carolina, Polaris Venture Partners of Waltham,
Massachusetts, Boston Millennia Partners of Boston,
Massachusetts, Hunt Ventures of Dallas, Texas, and Eastman
Ventures, the venture capital arm of Eastman Chemical Company of
Kingsport, Tennessee.
Athenix plans to use the proceeds to continue moving products
from their broad portfolio through field trials to registration.
Key products include major crops with enhanced traits such as
tolerance to important herbicides and resistances to pests such
as nematodes and insects. In October 2005 Athenix announced
results from very successful field trials of transgenic plants
containing proprietary glyphosate tolerance genes. The company
has discovered an important new class of genes that provides
extremely high tolerance to glyphosate.
"Athenix is an exciting investment opportunity," said Jerry
Caulder of Finistere Partners. "The company continues to make
excellent progress and is poised to become a key provider of
high-value traits for transgenic plants."
"Athenix is intensely focused on delivering the most advanced
trait stack products to the Crop Production Industry. Our
products provide growers with important alternatives essential
for improving agricultural productivity," said Mike Koziel,
President and CEO of Athenix Corp. "This new round of financing
is a great endorsement by our investors of our continued
progress and future promise."
Athenix is a leading biotechnology company that discovers and
develops novel products, technologies, and processes for the
agricultural and chemical businesses. Athenix is focused on
developing enhanced plants, microbes, enzymes and processes with
emphasis on two major market opportunities: 1) the discovery of
genes and proteins for novel input traits such as insect
resistance, nematode resistance, and herbicide tolerance, and
their use to develop transgenic plants for the Crop Production
Industry; and 2) the discovery of genes and proteins for use in
the Chemical and Animal Feed Industries. |